Serum anti‑GAPDH autoantibody levels reflect the severity of cervical lesions: A potential serum biomarker for cervical cancer screening

Xu,Mei Ling; Kim,Hyoung Jin; Kim,Seung Cheol; Ju,Woong; Kim,Yun Hwan; Chang,Kyu‑Ho; Kim,Hong‑Jin

doi:10.3892/ol.2019.10326

Serum anti‑GAPDH autoantibody levels reflect the severity of cervical lesions: A potential serum biomarker for cervical cancer screening

Authors:
- Mei Ling Xu
- Hyoung Jin Kim
- Seung Cheol Kim
- Woong Ju
- Yun Hwan Kim
- Kyu‑Ho Chang
- Hong‑Jin Kim
View Affiliations

Affiliations: Laboratory of Virology, College of Pharmacy, Chung‑Ang University, Dongjak‑Gu, Seoul 06974, Republic of Korea, Department of Obstetrics and Gynecology, Ewha Woman's University College of Medicine, Yangcheon‑Gu, Seoul 03760, Republic of Korea, Department of Biological Engineering, Inha University, Incheon 22212, Republic of Korea
Published online on: May 6, 2019 https://doi.org/10.3892/ol.2019.10326
Pages: 255-264
Copyright: © Xu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Recent studies have indicated that a certain level of autoantibodies may be essential for maintaining good health as well as preventing cancer development, and that the levels of serum autoantibodies can decline during malignant progression. The aim of the present study was to identify such an autoantibody‑based biomarker for screening cervical lesions. An autoantigen reactive with healthy female sera was detected in the cytosolic fraction of HeLa cells, a cervical cancer cell line, and identified. Serum immunoglobulin (Ig)‑G and IgM levels against the purified autoantigen in normal, cervical intraepithelial neoplasias (CINs) I, II and III, and cervical cancer were compared using ELISAs. The autoantigen in HeLa cells was identified to be GAPDH. The serum levels of anti‑HeLa‑GAPDH IgG decreased with increasing severity of cervical lesions, and similar decreases in IgM levels were revealed. Notably, the anti‑HeLa‑GAPDH IgG level was discovered to discriminate cervical cancer from normal samples with 80.0% sensitivity and 96.6% specificity. The serum anti‑HeLa‑GAPDH autoantibody level, as a single parameter, is a promising serum biomarker for screening cervical lesions.

View Figures

View References

1	Torre LA, Siegel RL, Ward EM and Jemal A: Global cancer incidence and mortality rates and trends-an update. Cancer Epidemiol Biomarkers Prev. 25:16–27. 2016. View Article : Google Scholar : PubMed/NCBI
2	Kim SM, Choi HS and Byun JS: Overall 5-year survival rate and prognostic factors in patients with stage IB and IIA cervical cancer treated by radical hysterectomy and pelvic lymph node dissection. Int J Gynecol Cancer. 10:305–312. 2000. View Article : Google Scholar : PubMed/NCBI
3	Kasamatsu T, Onda T, Sawada M, Kato T, Ikeda S, Sasajima Y and Tsuda H: Radical hysterectomy for FIGO stage I–IIB adenocarcinoma of the uterine cervix. Br J Cancer. 100:1400–1405. 2009. View Article : Google Scholar : PubMed/NCBI
4	Survival rates for cervical cancer by stage, . https://www.cancer.org/cancer/cervical-cancer/detection-diagnosis-staging/survival.html
5	Bulk S, Visser O, Rozendaal L, Verheijen RH and Meijer CJ: Incidence and survival rate of women with cervical cancer in the Greater Amsterdam area. Br J Cancer. 89:834–839. 2003. View Article : Google Scholar : PubMed/NCBI
6	Ibáñez R, Alejo M, Combalia N, Tarroch X, Autonell J, Codina L, Culubret M, Bosch FX and de Sanjosé S: Underscreened women remain overrepresented in the pool of cervical cancer cases in spain: A need to rethink the screening interventions. Biomed Res Int. 2015:6053752015. View Article : Google Scholar : PubMed/NCBI
7	Safaeian M, Solomon D and Castle PE: Cervical cancer prevention-cervical screening: Science in evolution. Obstet Gynecol Clin North Am. 34739–760. (ix)2007. View Article : Google Scholar : PubMed/NCBI
8	Karimi-Zarchi M, Peighmbari F, Karimi N, Rohi M and Chiti Z: A Comparison of 3 Ways of Conventional Pap Smear, Liquid-Based Cytology and Colposcopy vs Cervical Biopsy for Early Diagnosis of Premalignant Lesions or Cervical Cancer in Women with Abnormal Conventional Pap Test. Int J Biomed Sci. 9:205–210. 2013.PubMed/NCBI
9	Franco EL: Chapter 13: Primary screening of cervical cancer with human papillomavirus tests. J Natl Cancer Inst Monogr. 89–96. 2003. View Article : Google Scholar : PubMed/NCBI
10	Kulasingam SL, Havrilesky LJ, Ghebre R and Myers ER: Screening for cervical cancer: A modeling study for the US preventive services task force. J Low Genit Tract Dis. 17:193–202. 2013. View Article : Google Scholar : PubMed/NCBI
11	Marlow LA, Waller J and Wardle J: Barriers to cervical cancer screening among ethnic minority women: A qualitative study. J Fam Plann Reprod Health Care. 41:248–254. 2015. View Article : Google Scholar : PubMed/NCBI
12	McLaughlin-Drubin ME and Munger K: Viruses associated with human cancer. Biochim Biophys Acta. 1782:127–150. 2008. View Article : Google Scholar : PubMed/NCBI
13	Parkin DM: The global health burden of infection-associated cancers in the year 2002. Int J Cancer. 118:3030–3044. 2006. View Article : Google Scholar : PubMed/NCBI
14	Combes JD, Pawlita M, Waterboer T, Hammouda D, Rajkumar T, Vanhems P, Snijders P, Herrero R, Franceschi S and Clifford G: Antibodies against high-risk human papillomavirus proteins as markers for invasive cervical cancer. Int J Cancer. 135:2453–2461. 2014. View Article : Google Scholar : PubMed/NCBI
15	Coghill AE and Hildesheim A: Epstein-Barr virus antibodies and the risk of associated malignancies: Review of the literature. Am J Epidemiol. 180:687–695. 2014. View Article : Google Scholar : PubMed/NCBI
16	Mahieux R and Gessain A: Adult T-cell leukemia/lymphoma and HTLV-1. Curr Hematol Malig Rep. 2:257–264. 2007. View Article : Google Scholar : PubMed/NCBI
17	Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ and Muñoz N: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 189:12–19. 1999. View Article : Google Scholar : PubMed/NCBI
18	Luevano M, Bernard HU, Barrera-Saldaña HA, Trevino V, Garcia-Carranca A, Villa LL, Monk BJ, Tan X, Davies DH, Felgner PL and Kalantari M: High-throughput profiling of the humoral immune responses against thirteen human papillomavirus types by proteome microarrays. Virology. 405:31–40. 2010. View Article : Google Scholar : PubMed/NCBI
19	Joura EA, Ault KA, Bosch FX, Brown D, Cuzick J, Ferris D, Garland SM, Giuliano AR, Hernandez-Avila M, Huh W, et al: Attribution of 12 high-risk human papillomavirus genotypes to infection and cervical disease. Cancer Epidemiol Biomarkers Prev. 23:1997–2008. 2014. View Article : Google Scholar : PubMed/NCBI
20	Burd EM: Human papillomavirus and cervical cancer. Clin Microbiol Rev. 16:1–17. 2003. View Article : Google Scholar : PubMed/NCBI
21	Lutz HU: Homeostatic roles of naturally occurring antibodies: An overview. J Autoimmun. 29:287–294. 2007. View Article : Google Scholar : PubMed/NCBI
22	Schwartz-Albiez R, Monteiro RC, Rodriguez M, Binder CJ and Shoenfeld Y: Natural antibodies, intravenous immunoglobulin and their role in autoimmunity, cancer and inflammation. Clin Exp Immunol. 158 (Suppl 1):S43–S50. 2009. View Article : Google Scholar
23	Peng Y, Kowalewski R, Kim S and Elkon KB: The role of IgM antibodies in the recognition and clearance of apoptotic cells. Mol Immunol. 42:781–787. 2005. View Article : Google Scholar : PubMed/NCBI
24	Desmetz C, Mange A, Maudelonde T and Solassol J: Autoantibody signatures: Progress and perspectives for early cancer detection. J Cell Mol Med. 15:2013–2024. 2011. View Article : Google Scholar : PubMed/NCBI
25	Knight V, Merkel PA and O'Sullivan MD: Anticytokine autoantibodies: Association with infection and immune dysregulation. Antibodies. 5:2016.doi: 10.3390/antib5010003. View Article : Google Scholar
26	Wu J and Li L: Autoantibodies in Alzheimer's disease: Potential biomarkers, pathogenic roles, and therapeutic implications. J Biomed Res. 30:361–372. 2016.PubMed/NCBI
27	Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA and Harley JB: Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med. 349:1526–1533. 2003. View Article : Google Scholar : PubMed/NCBI
28	Lacombe J, Mange A and Solassol J: Use of Autoantibodies to Detect the Onset of Breast Cancer. J Immunol Res. 2014:5749812014. View Article : Google Scholar : PubMed/NCBI
29	Liu Y, Liao Y, Xiang L, Jiang K, Li S, Huangfu M and Sun S: A panel of autoantibodies as potential early diagnostic serum biomarkers in patients with breast cancer. Int J Clin Oncol. 22:291–296. 2017. View Article : Google Scholar : PubMed/NCBI
30	Huangfu M, Xu S, Li S, Sun B, Lee KH, Liu L and Sun S: A panel of autoantibodies as potential early diagnostic serum biomarkers in patients with cervical cancer. Tumour Biol. 37:8709–8714. 2016. View Article : Google Scholar : PubMed/NCBI
31	Tan EM and Zhang J: Autoantibodies to tumor-associated antigens: Reporters from the immune system. Immunol Rev. 222:328–340. 2008. View Article : Google Scholar : PubMed/NCBI
32	Zhang JY, Casiano CA, Peng XX, Koziol JA, Chan EK and Tan EM: Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens. Cancer Epidemiol Biomarkers Prev. 12:136–143. 2003.PubMed/NCBI
33	Tabuchi Y, Shimoda M, Kagara N, Naoi Y, Tanei T, Shimomura A, Shimazu K, Kim SJ and Noguchi S: Protective effect of naturally occurring anti-HER2 autoantibodies on breast cancer. Breast Cancer Res Treat. 157:55–63. 2016. View Article : Google Scholar : PubMed/NCBI
34	Shih NY, Lai HL, Chang GC, Lin HC, Wu YC, Liu JM, Liu KJ and Tseng SW: Anti-alpha-enolase autoantibodies are down-regulated in advanced cancer patients. Jpn J Clin Oncol. 40:663–669. 2010. View Article : Google Scholar : PubMed/NCBI
35	Van Hoesen K, Meynier S, Ribaux P, Petignat P, Delie F and Cohen M: Circulating GRP78 antibodies from ovarian cancer patients: A promising tool for cancer cell targeting drug delivery system? Oncotarget. 8:107176–107187. 2017. View Article : Google Scholar : PubMed/NCBI
36	Pinho SS and Reis CA: Glycosylation in cancer: Mechanisms and clinical implications. Nat Rev Cancer. 15:540–555. 2015. View Article : Google Scholar : PubMed/NCBI
37	Krueger KE and Srivastava S: Posttranslational protein modifications: Current implications for cancer detection, prevention, and therapeutics. Mol Cell Proteomics. 5:1799–1810. 2006. View Article : Google Scholar : PubMed/NCBI
38	He Y, Zhou Z, Hofstetter WL, Zhou Y, Hu W, Guo C, Wang L, Guo W, Pataer A, Correa AM, et al: Aberrant expression of proteins involved in signal transduction and DNA repair pathways in lung cancer and their association with clinical parameters. PLoS One. 7:e310872012. View Article : Google Scholar : PubMed/NCBI
39	Geradts J and Ingram CD: Abnormal expression of cell cycle regulatory proteins in ductal and lobular carcinomas of the breast. Mod Pathol. 13:945–953. 2000. View Article : Google Scholar : PubMed/NCBI
40	Zaenker P, Gray ES and Ziman MR: Autoantibody Production in Cancer-The Humoral Immune Response toward Autologous Antigens in Cancer Patients. Autoimmun Rev. 15:477–483. 2016. View Article : Google Scholar : PubMed/NCBI
41	Pappa KI, Lygirou V, Kontostathi G, Zoidakis J, Makridakis M, Vougas K, Daskalakis G, Polyzos A and Anagnou NP: Proteomic analysis of normal and cancer cervical cell lines reveals deregulation of cytoskeleton-associated proteins. Cancer Genomics Proteomics. 14:253–266. 2017. View Article : Google Scholar : PubMed/NCBI
42	Kontostathi G, Zoidakis J, Makridakis M, Lygirou V, Mermelekas G, Papadopoulos T, Vougas K, Vlamis-Gardikas A, Drakakis P, Loutradis D, et al: Cervical cancer cell line secretome highlights the roles of transforming growth factor-Beta-induced protein ig-h3, peroxiredoxin-2, and NRF2 on cervical carcinogenesis. Biomed Res Int. 2017:41807032017. View Article : Google Scholar : PubMed/NCBI
43	Demarco M, Lorey TS, Fetterman B, Cheung LC, Guido RS, Wentzensen N, Kinney WK, Poitras NE, Befano B, Castle PE, et al: Risks of CIN 2+, CIN 3+, and cancer by cytology and human papillomavirus status: The foundation of risk-based cervical screening guidelines. J Low Genit Tract Dis. 21:261–267. 2017. View Article : Google Scholar : PubMed/NCBI
44	Holowaty P, Miller AB, Rohan T and To T: Natural history of dysplasia of the uterine cervix. J Natl Cancer Inst. 91:252–258. 1999. View Article : Google Scholar : PubMed/NCBI
45	Ostör AG: Natural history of cervical intraepithelial neoplasia: A critical review. Int J Gynecol Pathol. 12:186–192. 1993. View Article : Google Scholar : PubMed/NCBI
46	McCredie MR, Sharples KJ, Paul C, Baranyai J, Medley G, Jones RW and Skegg DC: Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: A retrospective cohort study. Lancet Oncol. 9:425–434. 2008. View Article : Google Scholar : PubMed/NCBI
47	Macdonald IK, Parsy-Kowalska CB and Chapman CJ: Autoantibodies: Opportunities for early cancer detection. Trends Cancer. 3:198–213. 2017. View Article : Google Scholar : PubMed/NCBI
48	Zaenker P and Ziman MR: Serologic autoantibodies as diagnostic cancer biomarkers-a review. Cancer Epidemiol Biomarkers Prev. 22:2161–2181. 2013. View Article : Google Scholar : PubMed/NCBI
49	Pedersen JW and Wandall HH: Autoantibodies as Biomarkers in Cancer. Lab Medicine. 42:623–628. 2011. View Article : Google Scholar
50	de Oliveira GA, Rangel LP, Costa DC and Silva JL: Misfolding, aggregation, and disordered segments in c-Abl and p53 in human cancer. Front Oncol. 5:972015. View Article : Google Scholar : PubMed/NCBI
51	Shoenfeld Y and Toubi E: Protective autoantibodies: Role in homeostasis, clinical importance, and therapeutic potential. Arthritis Rheum. 52:2599–2606. 2005. View Article : Google Scholar : PubMed/NCBI
52	Siloşi I, Siloşi CA, Boldeanu MV, Cojocaru M, Biciuşcă V, Avrămescu CS, Cojocaru IM, Bogdan M and FolcuŢi RM: The role of autoantibodies in health and disease. Rom J Morphol Embryol. 57 (Suppl):633–638. 2016.PubMed/NCBI
53	Cohen M and Petignat P: Purified autoantibodies against glucose-regulated protein 78 (GRP78) promote apoptosis and decrease invasiveness of ovarian cancer cells. Cancer Lett. 309:104–109. 2011. View Article : Google Scholar : PubMed/NCBI
54	Díaz-Zaragoza M, Hernández-Ávila R, Viedma-Rodríguez R, Arenas-Aranda D and Ostoa-Saloma P: Natural and adaptive IgM antibodies in the recognition of tumor-associated antigens of breast cancer (Review). Oncol Rep. 34:1106–1114. 2015. View Article : Google Scholar : PubMed/NCBI
55	Nagele EP, Han M, Acharya NK, DeMarshall C, Kosciuk MC and Nagele RG: Natural IgG autoantibodies are abundant and ubiquitous in human sera, and their number is influenced by age, gender, and disease. PLoS One. 8:e607262013. View Article : Google Scholar : PubMed/NCBI
56	Krasnov GS, Dmitriev AA, Snezhkina AV and Kudryavtseva AV: Deregulation of glycolysis in cancer: Glyceraldehyde-3-phosphate dehydrogenase as a therapeutic target. Expert Opin Ther Targets. 17:681–693. 2013. View Article : Google Scholar : PubMed/NCBI
57	Hansen CN, Ketabi Z, Rosenstierne MW, Palle C, Boesen HC and Norrild B: Expression of CPEB, GAPDH and U6snRNA in cervical and ovarian tissue during cancer development. APMIS. 117:53–59. 2009. View Article : Google Scholar : PubMed/NCBI
58	Kim JW, Kim SJ, Han SM, Paik SY, Hur SY, Kim YW, Lee JM and Namkoong SE: Increased glyceraldehyde-3-phosphate dehydrogenase gene expression in human cervical cancers. Gynecol Oncol. 71:266–269. 1998. View Article : Google Scholar : PubMed/NCBI
59	Zheng J: Energy metabolism of cancer: Glycolysis versus oxidative phosphorylation (Review). Oncol Lett. 4:1151–1157. 2012. View Article : Google Scholar : PubMed/NCBI
60	Altenberg B and Greulich KO: Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes. Genomics. 84:1014–1020. 2004. View Article : Google Scholar : PubMed/NCBI
61	Liu K, Tang Z, Huang A, Chen P, Liu P, Yang J, Lu W, Liao J, Sun Y, Wen S, et al: Glyceraldehyde-3-phosphate dehydrogenase promotes cancer growth and metastasis through upregulation of SNAIL expression. Int J Oncol. 50:252–262. 2017. View Article : Google Scholar : PubMed/NCBI
62	Hao L, Zhou X, Liu S, Sun M, Song Y, Du S, Sun B, Guo C, Gong L, Hu J, et al: Elevated GAPDH expression is associated with the proliferation and invasion of lung and esophageal squamous cell carcinomas. Proteomics. 15:3087–3100. 2015. View Article : Google Scholar : PubMed/NCBI
63	Nicholls C, Pinto AR, Li H, Li L, Wang LH, Simpson R and Liu JP: Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) induces cancer cell senescence by interacting with telomerase RNA component. Proc Natl Acad Sci USA. 109:13308–13313. 2012. View Article : Google Scholar : PubMed/NCBI
64	Jung DW, Kim WH, Seo S, Oh E, Yim SH, Ha HH, Chang YT and Williams DR: Chemical targeting of GAPDH moonlighting function in cancer cells reveals its role in tubulin regulation. Chem Biol. 21:1533–1545. 2014. View Article : Google Scholar : PubMed/NCBI
65	Lea MA, Qureshi MS, Buxhoeveden M, Gengel N, Kleinschmit J and Desbordes C: Regulation of the proliferation of colon cancer cells by compounds that affect glycolysis, including 3-bromopyruvate, 2-deoxyglucose and biguanides. Anticancer Res. 33:401–407. 2013.PubMed/NCBI
66	Kim JW, Kim TE, Kim YK, Kim YW, Kim SJ, Lee JM, Kim IK and Namkoong SE: Antisense oligodeoxynucleotide of glyceraldehyde-3-phosphate dehydrogenase gene inhibits cell proliferation and induces apoptosis in human cervical carcinoma cell lines. Antisense Nucleic Acid Drug Dev. 9:507–513. 1999. View Article : Google Scholar : PubMed/NCBI
67	Chapman CJ, Healey GF, Murray A, Boyle P, Robertson C, Peek LJ, Allen J, Thorpe AJ, Hamilton-Fairley G, Parsy-Kowalska CB, et al: EarlyCDT^®-Lung test: Improved clinical utility through additional autoantibody assays. Tumour Biol. 33:1319–1326. 2012. View Article : Google Scholar : PubMed/NCBI
68	Jin Y, Kim SC and Kim HJ, Ju W, Kim YH and Kim HJ: Use of autoantibodies against tumor-associated antigens as serum biomarkers for primary screening of cervical cancer. Oncotarget. 8:105425–105439. 2017. View Article : Google Scholar : PubMed/NCBI
69	Révillion F, Pawlowski V, Hornez L and Peyrat JP: Glyceraldehyde-3-phosphate dehydrogenase gene expression in human breast cancer. Eur J Cancer. 36:1038–1042. 2000. View Article : Google Scholar : PubMed/NCBI
70	Tokunaga K, Nakamura Y, Sakata K, Fujimori K, Ohkubo M, Sawada K and Sakiyama S: Enhanced expression of a glyceraldehyde-3-phosphate dehydrogenase gene in human lung cancers. Cancer Res. 47:5616–5619. 1987.PubMed/NCBI
71	Hjerpe E, Egyhazi Brage S, Carlson J, Frostvik Stolt M, Schedvins K, Johansson H, Shoshan M and Avall-Lundqvist E: Metabolic markers GAPDH, PKM2, ATP5B and BEC-index in advanced serous ovarian cancer. BMC Clin Pathol. 13:302013. View Article : Google Scholar : PubMed/NCBI
72	Abdel-Haleem AM, Lewis NE, Jamshidi N, Mineta K, Gao X and Gojobori T: The emerging facets of non-cancerous warburg effect. Front Endocrinol (Lausanne). 8:2792017. View Article : Google Scholar : PubMed/NCBI